Sanofi has completed its $1.9-billion acquisition of Kadmon Holdings, a bio/pharmaceutical company, to expand its general medicines portfolio.

Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies. A key asset from Kadmon is Rezurock (belumosudil), a treatment for chronic graft-versus-host disease (cGVHD). In July (July 2021), the US Food and Drug Administration approved Rezurock for treating adult and pediatric patients 12 years and older with cGVHD after the failure of at least two prior lines of systemic therapy. Rezurock was launched in August (August 2021) in the US. Kadmon is also developing Rezurock for treating diffuse cutaneous systemic sclerosis, with a Phase II l trial currently ongoing.

Sanofi completed its acquisition of Kadmon through the merger of a wholly owned subsidiary, with Kadmon continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

Source: Sanofi